Third-line therapy for metastatic colorectal cancer

Cancer Chemotherapy and Pharmacology

Volumn 61, Issue 1, 2008, Pages 1-13

  Gundgaard, M G ^a   Soerensen, J B ^a   Ehrnrooth, E ^a,b  

^a Rigshospitalet   (Denmark)

^b NOVO NORDISK A S   (Denmark)

Author keywords

Advanced; Colorectal cancer; Review; Third line therapy

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; GIMERACIL; GROWTH FACTOR; IRINOTECAN; OTERACIL POTASSIUM; OXALIPLATIN; PANITUMUMAB; TEGAFUR; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; HYPERTENSION; INTESTINE PERFORATION; MEDICAL LITERATURE; METASTASIS; NEUTROPENIA; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SEPSIS; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; HUMANS; NEOPLASM METASTASIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 34848861113     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-007-0573-x     Document Type: Review

References (79)

1. Cunningham D, Findlay M (1993) The chemotherapy of colon cancer can no longer be ignored. Eur J Cancer 29A(15):2077-2079
2. de Gramont A, Bosset J-F, Milan C, Rougier P, Bouché O, Etienne P-L, Marvan F, Louvet C, Guillot T, François E, Bedenne L (1997) Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol 15(2):808-815
3. Cunningham D, Pyrhönen S, James RD, Punt CJA, Hickish TF, Heikkila R, Johannesen TB, Starkhammer H, Topham CA, Awad L, Jacques C, Herait P (1998) Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 352(9138):1413-1418
4. Rougier P, Van Cutsem E, Bajetta E, Niederle N, Possinger K, Labianca R, Navarro M, Morant R, Bleiberg H, Wils J, Awad L, Herait P, Jacques C (1998) Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 352(9138):1407-1412
5. de Gramont A, Vignoud J, Tournigand C, Louvet C, André T, Varette C, Raymond E, Moreau S, Le Bail N, Krulik M (1997) Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. Eur J Cancer 33(2):214-219
6. Rothenberg ML, Oza AM, Bigelowe RH, Berlin JD, Marshall JL, Ramanathan RK, Hart LL, Gupta S, Garay CA, Burger BG, Le Bail N, Haller DG (2003) Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. J Clin Oncol 21(11):2059-2069
7. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350(23):2335-2342
8. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351(4):337-345
9. US Food and Drug Administration. www.FDA.gov
10. Rowland KM, Pitot HC, Sargent DJ, Philip PA, Mitchell EP, Mailliard JA, Goldberg RM, Alberts SR (2005) Results of 3rd line therapy on N9841: a randomized phase III trial of oxaliplatin/5-fluorouracil (5FU)/leucovorin (FOLFOX4) versus irinotecan (CPT-11) in patients (pts) with advanced colorectal cancer (CRC) previously treated with prior 5FU chemotherapy. Proc ASCO, annual meeting, abstract no 3519
11. Van Cutsem E, Peeters M, Siena S, Humblet Y, Hendlisz A, Neyns B, Canon JL, Van Laethem JL, Maurel J, Richardson G, Wolf M, Amado RG (2007) Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 25(13):1658-1664
12. Kemeny N, Garay CA, Gurtler J, Hochster H, Kennedy P, Benson A, Brandt DS, Polikoff J, Wertheim M, Shumaker G, Hallman D, Burger B, Gupta S (2004) Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer. J Clin Oncol 22(23):4753-4761
13. Salek T (2005) Oxaliplatin, bolus 5-fluorouracil (5-FU) and leucovorin (LV/b-FOL) in heavily pretreated patients with metastatic colorectal cancer. National Cancer Institute Slovakia, the first "b-FOL" experience. ESMO, abstract no 70
14. Chau I, Webb A, Cunningham D, Hill M, Waters JS, Norman A, Massey A (2001) Oxaliplatin and protracted venous infusion of 5-fluorouracil in patients with advanced or relapsed 5-fluorouracil pretreated colorectal cancer. Br J Cancer 85(9):1258-1264
15. Abón G, Muňoz A, Rubio I, Manel MJ, Ferreiro J, Fernández R, Fuente N, López AG, Barceló R, López VG (2000) Third line oxaliplatin with leucovorin (LV) and continuous infusion 5-fluorouracil (5FU) in metastatic colorectal cancer. ESMO, abstract no 211P
16. Luppi G, Zanelli F, Di Stasi A, Bertolini F, Pifferi M (2002) Folfox 2 regimen in heavily pretreated patients with advanced colorectal cancer. Tumori 88(4):270-272
17. Martoni A, Mini E, Pinto C, Nobili S, Gentile AL, Dentico P, Angelelli B, Scicolone S, Piana E, Mazzei T (2001) Oxaliplatin and protracted continuous 5-fluorouracil infusion in patients with pretreated advanced colorectal carcinoma. Ann Oncol 12(4):519-524
18. Mosconi S, Cascinu S, Zaniboni A, Catalano V, Giordani P, Beretta GD, Martignoni G, Pancera G, Baldelli AM, Poletti P, Curti C, Labianca R (2000) The value of oxaliplatin in combination with continuous infusion ± bolus 5-fluorouracil and levo-folinic acid in metastatic colorectal cancer progressing after 5FU-based chemotherapy: a GISCAD (Italian Group for the study of digestive tract) cancer phase II trial. Tumori 86(6):465-469
19. Kallen K-J, Hofmann MAK, Timm A, Gödderz W, Galle PR, Heike M (2000) Weekly oxaliplatin, high-dose infusional 5-fluorouracil and folinic acid as palliative third-line therapy of advanced colorectal carcinoma. Z Gastroenterol 38:153-157
20. Giacchetti S, Zidani R, Chollet P, Dogliotti L, Kunstlinger F, Le Rol A, Garufi C, Brienza S, Focan C, Bertheault-Cvitkovic F, Misset J, Lévi F (2000) Chronotherapy of metastatic colorectal cancer (MCC) with 5-fluorouracil (5-FU)-leucovorin (LV)-oxaliplatin (L-OHP) as second to seventh line treatment. Proc ASCO, annual meeting, abstract no 1255
21. Croles N, Smorenburg CH, van Groeningen CJ, Giaccone G, Boven E (2004) FOLFOX3 in heavily pretreated patients with metastatic colorectal cancer. Neth J Med 62(7/8):242-245
22. Moehler M, Hoffmann T, Hildner K, Siebler J, Galle PR, Heike M (2002) Weekly oxaliplatin, high-dose folinic acid and 24h-5-fluorouracil (FUFOX) as salvage therapy in metastatic colorectal cancer patients pretreated with irinotecan and folinic acid/5-fluorouracil regimens. Z Gastroenterol 40:957-964
23. Bensmaïne MA, Marty M, de Gramont A, Brienza S, Lévi F, Ducreux M, François E, Gamelin E, Bleiberg H, Cvitkovic E (2001) Factors predicting efficacy of oxaliplatin in combination with 5-fluorouracil (5-FU) ± folinic acid in a compassionate-use cohort of 481 5-FU-resistant advanced colorectal cancer patients. Br J Cancer 85(4):509-517
24. Gervais H, Artru P, Louvet C, Tournigand C, Maindrault F, Garcia M-L, de Gramont A (2002) Reintroduction of irinotecan in pretreated patients with metastatic colorectal cancer. Proc ASCO, annual meeting, abstract no 688
25. Kim HJ, Kwon HC, Kim SH, Kim JS (2003) Irinotecan with biweekly, low-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for oxaliplatin pretreated metastatic colorectal cancer. Proc ASCO, annual meeting, abstract no 1196
26. Maindrault F, Louvet C, André T, Gilles V, Artru P, Tournigand C, Garcia M, Gervais H, Carola E, Krulik M, de Gramont A (2001) Time to disease control (TDC) to evaluate the impact on survival of three chemotherapy lines in metastatic colorectal cancer (MRC) based on 5-fluorouracil, oxaliplatin and irinotecan (GERCOR) Proc ASCO, annual meeting, abstract no 581
27. Stickel F, Jüngert B, Brueckl V, Schirner I, Brueckl WM, Männlein G, Hegewald J, Mühldorfer S, Bittorf B, Hohenberger W, Hahn EG, Wein A (2003) Weekly high-dose 5-fluorouracil as 24-h infusion and folinic acid (AIO) plus irinotecan as second- and third-line treatment in patients with colorectal cancer pre-treated with AIO plus oxaliplatin. Anticancer Drugs 14(9):745-749
28. Ardavanis AS, Ioannidis GN, Orphanos GS, Rigatos GA (2006) Salvage treatment with single-agent capecitabine in patients with heavily pretreated advanced colorectal cancer. Anticancer Res 26(2B):1669-1672
29. Gubanski M, Naucler G, Almerud A, Lidestahl A, Lind P ARM (2005) Capecitabine as third line therapy in patients with advanced colorectal cancer. Acta Oncol 44(3):236-239
30. Lim DH, Park YS, Park BB, Ji SH, Lee J, Park KW, Kang JH, Lee SH, Park JO, Kim K, Kim WS, Jung CW, Im YH, Kang WK, Park K (2005) Mitomycin-C and capecitabine as third-line chemotherapy in patients with advanced colorectal cancer: a phase II study. Cancer Chemother Pharmacol 56(1):10-14
31. Harba A, Jordan K, Kegel I, Behrens R, Grothey A, Schmoll HJ (2003) Capecitabine/mitomycin C as salvage therapy in oxaliplatin and CPT11 refractory advanced colorectal carcinoma (ACRC). Proc ASCO, annual meeting, abstract no 1335
32. Chong G, Dickson JLB, Cunningham D, Norman RA, Rao S, Hill ME, Price TJ, Oates J, Tebbutt N (2005) Capecitabine and mitomycin C as a 3rd line therapy for patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan. Br J Cancer 93(5):510-514
33. Jeung HC, Rha SY, Cho BC, Yoo NC, Roh JK, Roh WJ, Chung HC, Ahn JB (2006) A phase II trial of oral S-1 monotherapy in metastatic colorectal cancer after failure of irinotecan-and oxaliplatin containing regimens. Br J Cancer 95(12):1637-1641
34. Tsavaris N, Kosmas C, Vadiaka M, Kontos A, Fotia M, Angelopoulou A, Vrizidis N, Soulla M, Sougioultzis S, Koufos Ch (2002) Raltitrexed (Tomudex) administration in patients failing multiple prior chemotherapy regimens in advanced colorectal cancer: a pilot study. Invest New Drugs 20:133-136
35. Garcia M, Gilles V, Louvet C, Defrance R, Tournigand C, Artru P, Maindrault-Goebel F, de Gramont A, Krulik M (2000) Bi-weekly irinotecan (CPT-11) combined with raltitrexed ("Tomudex") treatment in heavily pre-treated patients with advanced colorectal cancer: a feasibility study. Proc ASCO, annual meeting, abstract no 987
36. Rosati G, Rossi A, Germano D, Reggiardo G, Manzione L (2003) Raltitrexed and mitomycin-C as third-line chemotherapy for colorectal cancer after combination regimens including 5-fluorouracil, irinotecan and oxaliplatin: a phase II study. Anticancer Res 23(3C):2981-2985
37. Lonardi S, Paris MK, Stefani M, Caroti C, D'Amico M, Jirillo A, Pronzato P, Gallo L, Monfardini S, Aschele C (2004) Gemcitabine (GEM) as salvage therapy in patients (pts) with advanced colorectal cancer (CRC) refractory to 5-fluorouracil (FU), irinotecan (IRI) and oxaliplatin (OXA). Proc ASCO, annual meeting, abstract no 3577
38. Pachon V, Garcia-Alfonso P, Iglesias L, Siso I, Abad G, Khosravi P, Diaz V, Perez-Manga G (2005) Gemcitabine plus continuous infusion of 5-FU for heavily pretreated advanced colorectal cancer patients. Phase I/II study. Proc ASCO, annual meeting, abstract no 3735
39. Hartmann JT, Oechsle K, Jäger E, Reis HE, Haag C, Niederle N, Wilke H-J, Pflüger K-H, Batran SAl, Büchele T, Hofheinz RD, Kanz L, Bokemeyer C (2004) Prospective multicenter phase II study of irinotecan as third line therapy in metastatic colorectal cancer and progression after bolus and infusional 5-fluorouracil. Anticancer Drugs 15(5):473-477
40. Benavides M, García-Alfonso P, Cobo M, Muňoz-Martín A, Gil-Calle S, Carabantes F, Villar E, Graupera J, Balcells M, Pérez-Manga G (2004) Weekly irinotecan (CPT-11) in 5-FU heavily pretreated and poor-performance-status patients with advanced colorectal cancer. Med Oncol 21(3):255-262
41. Gholam D, Giacchetti S, Brezault Bonnet C, Bouchahda M, Hauteville D, Adam R, Decot B, Ghémard O, Kustlinger F, Jasmin C, Levi F (2006) Chronomodulated irinotecan, oxaliplatin, and leucovorin-modulated 5-fluorouracil as ambulatory salvage therapy in patients with irinotecan-and oxaliplatin-resistant metastatic colorectal cancer. Oncologist 11(10):1072-1080
42. Polus M, Peeters M, Baert F, Vergauwe P, Kalantari H, Hendrickx K, Collignon J, van Maele P, Vandeputte L, van Laethem JL (2004) CPT-11 and mitomycin-C in heavily pre-treated patients with metastatic colorectal cancer: a Belgian multicentre phase II study. Proc ASCO, annual meeting, abstract no 3716
43. Schulz J, Keller A, Canfield V, Parker G, Douglass E (2004) ZD9331 as second- or third-line therapy in patients with advanced colorectal cancer: a phase II multicenter trial. Am J Clin Oncol 27(4):337-342
44. Gollasch H, Gebauer B, Sturm I, Thuss-Patience P, Pink D, Stroszczynski C, Kretzschmar A (2004) Hepatic artery infusion (HAI) of oxaliplatin (Ox) as third and fourth-line therapy for patients with hepatic metastases (M) from colorectal cancer (CRC) pretreated with systemic Ox. Proc ASCO, annual meeting, abstract no 3695
45. Mirtsching B, Headlee C, Beasley S, Teel C, Jackson D (2004) Cetuximab single-agent activity in refractory metastatic colorectal cancer: single-center experience. Proc ASCO, annual meeting, abstract no 3703
46. Lenz HJ, Van Cutsem E, Khambata-Ford S, Mayer RJ, Gold P, Stella P, Mirtsching B, Cohn AL, Pippas AW, Azarnia N, Tsuchihashi Z, Mauro DJ, Rowinsky EK (2006) Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. J Clin Oncol 24(30):4914-4921
47. Mirtsching BC, Cichon J, Beasly S, Teel C, Jackson D, Headlee C (2005) Cetuximab in refractory metastatic colorectal cancer: analysis of efficacy and response by patient and disease variables. Proc ASCO, gastrointestinal symposium, abstract no 205
48. Vincenzi B, Santini D, Rabitti C, Coppola R, Beomonte Zobel B, Trodella L, Tonini G (2006) Cetuximab and irinotecan as third-line therapy in advanced colorectal cancer patients: a single centre phase II trial. Br J Cancer 94(6):792-797
49. Grande C, Mel JR, Salgado M, Reboredo M, Candamio S, Fernandez I, Quintero G, Huidobro G, Firvida JL, Valladares M (2006) Multicenter phase II study of cetuximab and irinotecan as third line chemotherapy in patients (pts) with metastatic colorectal cancer (MCRC) previously treated with both irinotecan and oxaliplatin regimens. Proc ASCO, annual meeting, abstract no 13551
50. Grothe W, Arnold D, Peinert S, Voigt W, Mantovani Loeffler L, Siewczynski R, Steps G, Boehme J, Graeven U, Schmoll H (2005) Cetuximab with oxaliplatin and capecitabine (CAPOX) in patients with metastatic colorectal cancer (mCRC) refractory to standard chemotherapy. Proc ASCO, annual meeting, abstract no 3669
51. Chen HX, Mooney M, Boron M, Vena D, Mosby K, Grochow L, Jaffe C, Rubinstein L, Zwiebel J, Kaplan RS (2006) Phase II multicenter trial of bevacizumab plus fluorouracil and leucovorin in patients with advanced refractory colorectal cancer: an NCI treatment referral center trial TRC-0301. J Clin Oncol 24(21):3354-3360
52. Emmanouilides C, Pegram M, Robinson R, Hecht R, Kabbinavar F, Isacoff W (2004) Anti-VEGF antibody bevacizumab (Avastin) with 5FU/LV as third line treatment for colorectal cancer. Tech Coloproctol 8(Suppl 1):50-52
53. Peinert S, Arnold D, Grothe W, Lesske J, Siewczynski R, Schädlich B, Kegel T, Behrmann C, Schmoll H-J (2005) Salvage therapy with bevacizumab, capecitabin, and mitomycin C (BECAM) for patients with metastatic colorectal or gastric cancer refractory to 5fluorouracil, oxaliplatin, irinotecan, and cetuximab. ECCO abstract no 793
54. Dorligschaw O, Kegel T, Jordan K, Harba A, Grothey A, Schmoll H-J (2003) ZD1839 (Iressa)-based treatment as last-line therapy in patients with advanced colorectal cancer (ACRC). Proc ASCO, annual meeting, abstract no 1494
55. Hecht J, Mitchell E, Baranda J, Malik I, Richards D, Navale L, D'Avirro P, Amado R (2006) Panitumumab antitumor activity in patients (pts) with metastatic colorectal cancer (mCRC) expressing low (1-9%) or negative (<1%) levels of epidermal growth factor receptor (EGFr). Proc ASCO, annual meeting, abstract no 3547
56. Berlin J, Neubauer M, Swanson P, Harker G, Burris H, Hecht JR, Navale L (2006) Panitumumab antitumor activity in patients (pts) with metastatic colorectal cancer (mCRC) expressing ≥10% epidermal growth factor receptor (EGFr). Proc ASCO, annual meeting, abstract no 3548
57. Gebbia V, Del Prete S, Borsellino N, Ferraù F, Tralongo P, Verderame F, Leonardi V, Capasso E, Maiello E, Bordonaro R, Stinco S, Aqostara B, Barone C (2006) Efficacy and safety of cetuximab/irinotecan in chemotherapy-refractory metastatic colorectal adenocarcinomas: a clinical practice setting, multicenter experience. Clin Colorectal Cancer 5(6):422-428
58. Levi F, Karaboue A, Jasmin C, Innominto P, Machover D, Kunstlinger F, Castagne V, Adam R, Guettier C, Bouchahda M (2005) Cetuximab reversal of chemotherapy resistance in patients with extensively pretreated metastatic colorectal cancer treated at Paul-Brousse hospital. ECCO abstract no 710
59. NCI 2007. www.cancer.gov. Health professional version
60. Tournigand C, André T, Achille E, Lledo G, Flesh M, Mery-Mignard D, Quinaux E, Couteau C, Buyse M, Ganem G, Landi B, Colin P, Louvet C, de Gramont A (2004) FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomised GERCOR study. J Clin Oncol 22(2):229-237
61. Adjei AA (1999) A review of the pharmacology and clinical activity of new chemotherapy agents for the treatment of colorectal cancer. Br J Clin Pharmacol 48(3):265-277
62. Goetz MP, Grothey A (2004) Developments in combination chemotherapy for colorectal cancer. Expert Rev Anticancer Ther 4(4):627-637
63. Grothey A, Sargent D, Goldberg RM, Schmoll H-J (2004) Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 22(7):1209-1214
64. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, de Braud F, Wilson C, Morvan F, Bonetti A (2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18(16):2938-2947
65. Rothenberg ML, Meropol NJ, Poplin EA, Van Cutsem E, Wadler S (2001) Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel. J Clin Oncol 19(18):3801-3807
66. Cocconi G, Cunningham D, Van Cutsem E, Francois E, Gustavsson B, van Hazel G, Kerr D, Possinger K, Hietschold SM (1998) Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. Tomudex colorectal cancer study group. J Clin Oncol 16(9):2943-2952
67. Hejna M, Kornek GV, Raderer M, Depisch D, Brodowicz T, Fiebiger WC, Scheithauer W (1998) Reinduction therapy with the same cytostatic regimen in patients with advanced colorectal cancer. Br J Cancer 78(6):760-764
68. www.Merck.de. 2006
69. Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer J, Mitchell P, Alberts SR, Schwartz MA, Benson AB, Eastern Cooperative Oncology Group Study E3200 (2007) Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 25(12):1539-1544
70. Saltz LB, Lenz H, Kindler H, Hochster H, Wadler S, Hoff P, Kemeny N, Hollywood E, Gonen M, Chen H (2005) Interim report of randomized phase II trial of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer. Proc ASCO, Gastrointestinal Cancers Symposium, abstract no 169b
71. Hecht JR, Patnaik A, Malik I Venook A, Berlin J, Croghan G, Wiens BL, Visonneau S, Jerian S, Meropol NJ (2004) ABX-EGF monotherapy in patients (pts) with metastatic colorectal cancer (mCRC): an updated analysis. Proc ASCO, annual meeting, abstract no 3511
72. Goldberg RM, Rothenberg ML, Van Cutsem E, Benson AB, Blanke CD, Diasio RB, Grothey A, Lenz H-J, Meropol NJ, Ramanathan RK, Becerra CHR, Wickham R, Armstrong D, Viele C (2007) The continuum of care: a paradigm for the management of metastatic colorectal cancer. Oncologist 12(1):38-50
73. Grothey A, Deschler B, Kroening H, Ridwelski K, Reichardt P, Kretzscmar A, Clemens M, Hirschmann W, Lorenz M, Asperger W, Buechele T, Schmoll H-J (2002) Phase III study of bolus 5-fluorouracil (5-FU)/folinic acid (FA) (MAYO) vs. weekly high-dose 24h 5-FU infusion/FA + oxaliplatin (OXA) (FUFOX) in advanced colorectal cancer (ACRC). Proc ASCO, annual meeting, abstract no 512
74. Cheeseman SL, Joel SP, Chester JD, Wilson G, Dent JT, Richards FJ, Seymour MT (2002) A "modified de Gramont" regimen of fluorouracil, alone and with oxaliplatin, for advanced colorectal cancer. Br J Cancer 87(4):393-399
75. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL, Miller LL (2000) Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan study group. N Engl J Med 343(13):905-914
76. Giacchetti S, Bjarnason G, Garufi C, Genet D, Iacobelli S, Tampellini M, Smaaland R, Focan C, Coudert B, Humblet Y, Canon JL, Adenis A, Lo Re G, Carvalho C, Schueller J, Anciaux N, Lentz MA, Baron B, Gorlia T, Levi F (2006) Phase III trial comparing 4-day chronomodulated therapy versus 2-day conventional delivery of fluorouracil, leucovorin, and oxaliplatin as first-line chemotherapy of metastatic colorectal cancer: the European Organisation for Research and Treatment of Cancer Chronotherapy Group. J Clin Oncol 24(22):3562-3569
77. Maindrault-Goebel F, de Gramont A, Louvet C, Andre T, Carola E, Gilles V, Lotz JP, Tournigand C, Mabro M, Molitor JL, Artru P, Izrael V, Krulik M (2000) Evaluation of oxaliplatin dose intensity in bimonthly leucovorin and 48-hour 5-fluorouracil continuous infusion regimens (FOLFOX) in pretreated metastatic colorectal cancer. Oncology Multidisciplinary Research Group (GERCOR). Ann Oncol 11(11):1477-1483
78. Tournigand C, Cervantes A, Figer A, Lledo G, Flesch M, Buyse M, Mineur L, Carola E, Etienne PL, Rivera F, Chirivella I, Perez-Staub N, Louvet C, Antré T, Tabah-Fisch I, de Gramont A (2006) OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-GO fashion advanced colorectal cancer-a GERCOR study. J Clin Oncol 24(3):394-400
79. Cassidy J, Tabernero J, Twelves C, Brunet R, Butts C, Conroy T, Debraud F, Figer A, Grossmann J, Sawada N, Schöffski P, Sobrero A, Van Cutsem E, Díaz-Rubio E (2004) XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol 22(11):2084-2091